These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34318591)

  • 1. Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort.
    Fabbiani M; Rossetti B; Ciccullo A; Oreni L; Lagi F; Celani L; Colafigli M; De Vito A; Mazzitelli M; Dusina A; Durante M; Montagnani F; Rusconi S; Capetti A; Sterrantino G; D'Ettorre G; Di Giambenedetto S;
    HIV Med; 2021 Oct; 22(9):843-853. PubMed ID: 34318591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.
    Gagliardini R; Baccini M; Modica S; Montagnani F; Zanelli G; Borghetti A; Dreassi E; Lombardi F; Pecorari M; Borghi V; Callegaro A; Micheli V; Lodi MA; Rossetti B; Zazzi M;
    J Glob Antimicrob Resist; 2022 Mar; 28():274-281. PubMed ID: 35092828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
    d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
    J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
    Gianotti N; Poli A; Nozza S; Galli L; Galizzi N; Ripa M; Merli M; Carbone A; Spagnuolo V; Lazzarin A; Castagna A
    BMC Infect Dis; 2017 Nov; 17(1):723. PubMed ID: 29145807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort.
    Teira R; Diaz-Cuervo H; Aragão F; Castaño M; Romero A; Roca B; Montero M; Galindo MJ; Muñoz-Sánchez MJ; Espinosa N; Peraire J; Martínez E; de la Fuente B; Domingo P; Deig E; Merino MD; Geijo P; Estrada V; Sepúlveda MA; García J; Berenguer J; Currán A
    Infect Dis Ther; 2022 Jun; 11(3):1177-1192. PubMed ID: 35399147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Experience with Two-Drug Regimens in HIV-1-Infected Patients Beyond the Indication of Clinical Trials: 48 Weeks' Results.
    Arancón Pardo A; Moreno Palomino M; Jiménez-Nácher I; Moreno F; González Fernández MÁ; González-García J; Herrero Ambrosio A
    AIDS Res Hum Retroviruses; 2021 Oct; 37(10):761-767. PubMed ID: 34465135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.
    Marcelin AG; Charpentier C; Bellecave P; Abdi B; Chaix ML; Ferre V; Raymond S; Fofana D; Bocket L; Mirand A; Le Guillou-Guillemette H; Montes B; Amiel C; Pallier C; Fafi-Kremer S; De Monte A; Alessandri-Gradt E; Scholtes C; Maillard A; Jeulin H; Bouvier-Alias M; Roussel C; Dos Santos G; Signori-Schmuck A; Dina J; Vallet S; Stefic K; Soulié C; Calvez V; Descamps D; Flandre P;
    J Antimicrob Chemother; 2021 Aug; 76(9):2400-2406. PubMed ID: 34100068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study.
    Rossetti B; Fabbiani M; Di Carlo D; Incardona F; Abecasis A; Gomes P; Geretti AM; Seguin-Devaux C; Garcia F; Kaiser R; Modica S; Shallvari A; Sönnerborg A; Zazzi M;
    J Antimicrob Chemother; 2021 Aug; 76(9):2394-2399. PubMed ID: 34212176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
    Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
    Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability of integrase inhibitors in a real-life setting.
    Peñafiel J; de Lazzari E; Padilla M; Rojas J; Gonzalez-Cordon A; Blanco JL; Blanch J; Marcos MA; Lonca M; Martinez-Rebollar M; Laguno M; Tricas A; Rodriguez A; Mallolas J; Gatell JM; Martinez E
    J Antimicrob Chemother; 2017 Jun; 72(6):1752-1759. PubMed ID: 28333231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects.
    Giacomelli A; Ranzani A; Oreni L; Gervasi E; Lupo A; Ridolfo AL; Galli M; Rusconi S
    Drug Des Devel Ther; 2019; 13():2271-2282. PubMed ID: 31371921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
    Deschanvres C; Reynes J; Lamaury I; Rey D; Palich R; Bani-Sadr F; Robineau O; Duvivier C; Hocqueloux L; Cuzin L; Joly V; Raffi F; Cabie A; Allavena C;
    J Antimicrob Chemother; 2021 Dec; 77(1):196-204. PubMed ID: 34651192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
    Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
    Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV.
    O'Halloran JA; Wang K; Spence AB; Williams DW; Dastgheyb R; Fitzgerald KC; Kamkwalala AR; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Lahiri CD; Sheth AN; Xu Y; Rubin LH
    J Acquir Immune Defic Syndr; 2021 Apr; 86(5):593-599. PubMed ID: 33394812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
    Cento V; Perno CF
    J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus.
    Castagna A; Ferrara M; Galli L; Comi L; Sterrantino G; Cenderello G; Zaccarelli M; Focà E; Roncadori A; Lazzarin A;
    J Antimicrob Chemother; 2018 Jan; 73(1):177-182. PubMed ID: 29077927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
    Dueñas-Gutiérrez C; Buzón L; Pedrero-Tomé R; Iribarren JA; De Los Santos I; De la Fuente S; Pousada G; Moran MA; Moreno E; Ferreira E; Gómez J; Troya J
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
    Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
    J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
    Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
    Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokines assets in PLWH in two-drug dolutergravir based or three-drug antiretroviral regimen.
    Falasca K; Ucciferri C; Di Gasbarro A; Borrelli P; Di Nicola M; Frisenda C; Costantini E; Aielli L; Reale M; Vecchiet J
    BMC Infect Dis; 2024 Jul; 24(1):665. PubMed ID: 38961336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.